Immunomodulators in the treatment of cutaneous lymphoma

Journal of the European Academy of Dermatology and Venereology

Volumn 13, Issue 2, 1999, Pages 83-90

  Rogalski, Christina ^a   Dummer, Reinhard ^a   Burg, Günter ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Cutaneous lymphoma; Immunointervention; Immunomodulators; Interferon; Interleukin

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; CYCLOSPORIN A; DENILEUKIN DIFTITOX; ETRETINATE; GAMMA INTERFERON; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERFERON; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ANTIBODY; ISOTRETINOIN; MELANOMA VACCINE; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT ALPHA INTERFERON; RETINOID; TAGRETIN; THYMOPENTIN; THYMOPOIETIN; TOXIN; UNCLASSIFIED DRUG;

AUTOLOGOUS BONE MARROW TRANSPLANTATION; DRUG EFFICACY; HUMAN; IMMUNOMODULATION; NONHUMAN; PHOTOCHEMOTHERAPY; PRIORITY JOURNAL; PUVA; REVIEW; SKIN LYMPHOMA;

ANTIBODIES, MONOCLONAL; BONE TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; INTERFERONS; INTERLEUKIN-2; LYMPHOMA; SKIN NEOPLASMS; TRANSPLANTATION, AUTOLOGOUS;

EID: 0032859224     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0926-9959(99)00081-1     Document Type: Review

References (45)

1. Nestle FO, Nickoloff BJ. Role of dendritic cells in benign and malignant lymphocytic infiltrates of the skin. Dermatol Clin 1994;12(2):271-282.
2. Dummer R, Schwarz T. Cytokines as regulatory proteins in lymphoproliferative skin infiltrates. Derm Clin 1994;12:283-294.
3. Burg G, Dummer R, Wilhelm M, et al. A subcutaneous delta-positive T-cell lymphoma that produces interferon gamma. N Engl J Med 1991;325(15):1078-1081.
4. Dummer R, Geertsen R, Ludwig E, et al. Sézary Syndrome T-Helper 2 Cytokines and Accessory Factor-1 (AF-1). Leukemia Lymphoma 1998;28:515-522.
5. Olsen EA, Bunn PA. Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995;9(5):1089-1107.
6. Kirkwood JM, Ernstoff MS. Interferons in the treatment of human cancer. J Clin Oncol 1984;2(4):336-352.
7. Bunn Jr PA, Foon KA, Ihde DC, et al. Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med 1984;101(4):484-487.
8. Kohn EC, Steis RG, Sausville EA, et al. Phase II trial of intermittent high- dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome. J Clin Oncol 1990;8(1):155-160.
9. Olsen EA, Rosen ST, Vollmer RT, et al. Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol 1989;20(3):395-407.
10. Dummer R, Heald PW, Nestle FO, et al. Sézary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon- gamma receptor beta-chain). Blood 1996;88(4):1383-1389.
11. Bunn Jr PA, Ihde DC, Foon KA. Recombinant interferon alfa-2a, an active agent in advanced cutaneous T-cell lymphomas. Int J Cancer Suppl 1987;1:9-13.
12. Burg G, Dummer R, Nestle F. Cutaneous Lymphomas. In: Burg G, Dummer R, editors. Strategies for Immunointerventions in Dermatology, Berlin: Springer, 1997. pp. 321-335.
13. Vonderheid EC, Thompson R, Smiles KA, et al. Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. Arch Dermatol 1987;123(6):757-763.
14. Wolff JM, Zitelli JA, Rabin BS, et al. Intralesional interferon in the treatment of early mycosis fungoides. J Am Acad Dermatol 1985;13(4):604-612.
15. Dummer R, Muller W, Nestle F, et al. Formation of neutralizing antibodies against natural interferon beta, but not against interferon gamma during adjuvant therapy for high risk malignant melanoma patients. Cancer 1991;67:2300-2304.
16. Rajan GP, Seifert B, Prümer O, Joller-Jemelka HI, Burg G, Dummer R. Incidence and in-vivo relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon-alpha 2a combined with acetretin or PUVA. Arch Dermatol Res 1996;288:543-548.
17. Zinzani PL, Mazza P, Gherlinzoni F. Beta interferon in the treatment of mycosis fungoides. Haematologica 1988;73(6):547-548.
18. Kaplan EH, Rosen ST, Norris DB, et al. Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 1990;82(3):208-212.
19. Yamamoto T, Sasaki G, Sato T, et al. Cytokine profile of tumor cells in mycosis fungoides: successful treatment with intra-lesional interferon- gamma combined with chemotherapy. J Dermatol 1995;22(9):650-654.
20. Marolleau JP, Baccard M, Flageul B, et al. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma. Arch Dermatol 1995;131(5):574-579.
21. Nagatani T, Kin ST, Baba N, et al. A case of cutaneous T cell lymphoma treated with recombinant interleukin 2 (rIL-2). Acta Derm Venereol 1988;68(6):504-508.
22. Cooper DL, Braverman IM, Sarris AH, et al. Cyclosporine treatment of refractory T-cell lymphomas. Cancer 1993;71(7):2335-2341.
23. Vanrenterghem Y. The use of mycophenolate mofetil (cell-cept) in renal transplantation (clinical conference). Nephron 1997;76(4):392-399.
24. Bunn Jr PA, Hoffman SJ, Norris D, et al. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med 1994;121(8):592-602.
25. Dillman RO, Shawler DL, Dillman JB, et al. Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J Clin Oncol 1984;2(8):881-891.
26. Ramos EL, Milford EL, Kirkman RL, et al. Differential IL-2 receptor expression in renal allograft recipients treated with an anti-IL-2-receptor antibody. Transplantation 1989;48(3):415-420.
27. Zeitoun C, Baccard M, Marolleau JP, et al. Bone marrow autograft in the treatment of cutaneous lymphoma. Ann Dermatol Venereol 1996;123(2):79-84.
28. Moreau P, LeTortorec S, Mahe MA, et al. Autologous bone marrow transplantation using TBI and CBV for disseminated high/intermediate grade cutaneous non-epidermotropic non-Hodgkin's lymphoma. Bone Marrow Transplant 1994;14(5):775-778.
29. Bigler RD, Crilley P, Micaily B, et al. Autologous bone marrow transplantation for advanced stage mycosis fungoides. Bone Marrow Transplant 1991;7(2):133-137.
30. Chen Y, Wang CH, Huang SC. Autologous bone marrow transplantation after supralethal dose of total body irradiation in a case of mycosis fungoides. Taiwan I Hsueh Hui Tsa Chih 1968;85:304-314.
31. Kuzel TM, Rosen ST, Gordon LI, et al. Phase I trial of the diphtheria toxin/interleukin-2 fusion protein DAB486IL-2: efficacy in mycosis fungoides and other non-Hodgkin's lymphomas. Leuk Lymphoma 1993;11(5-6):369-377.
32. Cohen R, Jaffe ES, Stetler Stevenson MA, et al. Bilateral adrenal hemorrhage and adrenal insufficiency in a patient with lymphomatous adrenal infiltration following administration of a fusion toxin (DAB(486)interleukin-2). J Immunother 1994;16(3):229-233.
33. Hesketh P, Caguioa P, Koh H, et al. Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma. J Clin Oncol 1993;11(9):1682-1690.
34. Foss FM, Borkowski TA, Gilliom M, et al. Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sézary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study. Blood 1994;84(6):1765-1774.
35. Nichols J, Foss F, Kuzel TM, et al. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Eur J Cancer 1997;33(Suppl. 1):S34-S36.
36. Przybilla B, Burg G, Schmoeckel C, et al. Treatment of cutaneous T-cell lymphomas with TP-5. Evaluation of the clinical effect in 8 patients. Acta Derm Venereol 1983;63(6):524-529.
37. Bernengo MG, Doveil GC, Meregalli M, et al. Immunomodulation and Sezary syndrome: experience with thymopentin (TP-5). Br J Dermatol 1988;119(2):207-221.
38. Foss FM, Kuzel TM. Experimental therapies in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995;9(5):1127-1137.
39. Kessler JF, Jones SE, Levine N, et al. Isotretinoin and cutaneous helper T- cell lymphoma (mycosis fungoides). Arch Dermatol 1987;123(2):201-204.
40. Zachariae H, Grunnet E, Thestrup Pedersen K, et al. Oral retinoid in combination with bleomycin, cyclophosphamide, prednisone and transfer factor in mycosis fungoides. Acta Derm Venereol 1982;62(2):162-164.
41. Molin L, Thomsen K, Volden G, et al. Oral retinoids in mycosis fungoides and Sézary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 1987;67(3):232-236.
42. Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 1987;316(6):297-303.
43. Heald P, Rook A, Perez M, et al. Treatment of erythrodermic cutaneous T- cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol 1992;27(3):427-433.
44. Bhardwaj N, Bender A, Gonzalez N, et al. Stimulation of human anti-viral CD8+ cytolytic T lymphocytes by dendritic cells. Adv Exp Med Biol 1995;378:375-397.
45. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2(1):52-58.